<DOC>
	<DOCNO>NCT01092039</DOCNO>
	<brief_summary>The purpose study assess efficacy safety XIGO administer orally , three time day , compare placebo patient common cold .</brief_summary>
	<brief_title>Safety Efficacy Study Oral XIGO Tablets Treat The Common Cold</brief_title>
	<detailed_description>The common cold one frequent human illness show result significant morbidity economic loss . At present time truly effective therapy available . Therapeutic intervention compound zinc find helpful however well report side-effects prevent extensive use . Based several year anecdotal clinical evidence show XIGO effective alleviating symptom common cold-the finding support competent reliable evidence vivo vitro clinical trial study individual active ingredient formulation , propose XIGO , administer orally , direct stimulatory effect multiple component immune system . It propose stimulation increase immune cell population well functionality observe cell molecule innate adaptive response .</detailed_description>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Must good health clinical judgment investigator , cold symptom Must cumulative score 2 high , large 6 , symptom severity rat 0=absent , 1=mild , 2= moderate , 3=severe eight symptom : sneezing , nasal discharge , nasal obstruction , sore throat , cough , headache , malaise chillness . At least one first four `` cold specific '' symptom must present , none symptom present 12 hour . Must enter trial within 12 hour symptoms onset . Aged 1850 year , ( inclusive ) , visit 1 . Subjects must understand sign date inform consent form prior study related procedure perform . Subjects must capable understand follow direction . Subjects take medication , birth control , , opinion investigator , could influence purpose , integrity outcome trial . Premenopausal woman ( last menstruation &lt; =1 year prior ICF ) nursing pregnant childbearing potential , opinion investigator , practice acceptable method birth control , plan continue use method throughout study . A history adverse reaction OTC drug personal care product . Subjects use systemic steroid least 6 week prior trial initiation trial . A medical history autoimmune disease , include Type 1 Type 2 diabetes HIV . Treatment immunosuppressive drug exception cyclosporine keratitis sicca .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Common Cold</keyword>
	<keyword>Cold Virus</keyword>
	<keyword>Feeling sick</keyword>
	<keyword>Influenza</keyword>
</DOC>